RT Journal Article
SR Electronic
A1 Nichols, Emma Hitt
T1 Management of Targeted Drug Resistance in NSCLC
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 3
SP 24
OP 25
DO 10.1177/155989771403015
UL http://mdc.sagepub.com/content/14/3/24.abstract
AB In some cases of non—small cell lung cancer (NSCLC), mutations in oncogenes appear to be the underlying mechanism of lung cancer development. Specifically targeted therapies are promising in the treatment of NSCLC, but mutations in oncogenic drivers can result in drug resistance. This article discusses drug resistance to ALK and ROS1 inhibitors, as well as BRAF and HER2 mutations that result in drug resistance.